<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160978</url>
  </required_header>
  <id_info>
    <org_study_id>T1020SIMVASTATIN</org_study_id>
    <nct_id>NCT01160978</nct_id>
  </id_info>
  <brief_title>Donor Simvastatin Treatment in Organ Transplantation</brief_title>
  <acronym>SIMVA</acronym>
  <official_title>Donor Simvastatin Treatment in Organ Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the effects of simvastatin treatment on
      ischemia-reperfusion injury in the context of cardiac-, lung-, kidney-, and liver
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study hypothesis is that the per orally administered donor-related simvastatin treatment
      protects the transplanted organs for cold ischemia-related injury and ischemia-reperfusion
      injury. Also, it potentially decreases natural immune activity, rejection activation and
      thus improves long-term prognosis.

      80 mg simvastatin is administered into donor circulation through the nasogastric tube 4-6
      hours prior organ harvesting. The impact of donor simvastatin treatment is investigated and
      analyzed by several specific blood samples and biopsies that are taken from the recipient at
      the various time-points during the perioperative and postoperative phase. The randomized and
      blinded control group includes heart-, lung-, kidney-, and liver recipients whose organ
      donors have not received any statin medication prior organ harvesting.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preoperative donor simvastatin treatment reduces ischemia-reperfusion injury</measure>
    <time_frame>0-20 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preoperative donor simvastatin treatment reduces natural immune activity and the rate of rejection</measure>
    <time_frame>0-20 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Heart Failure</condition>
  <condition>Respiratory Failure</condition>
  <condition>Liver Failure</condition>
  <condition>Kidney Failure</condition>
  <condition>Transplantation</condition>
  <arm_group>
    <arm_group_label>Simvastatin treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients whose organ donor have received statin treatment prior transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The patients whose organ donor has not received statin treatment prior organ transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>80 mg simvastatin through nasogastric tube prior organ harvesting</description>
    <arm_group_label>Simvastatin treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart, lung, liver or kidney transplantation

        Exclusion Criteria:

          -  Preoperative statin treatment of the donor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janne J Jokinen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Hospital, Dept. of Cardiothoracic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Hospital. Dept. of Cardiothoracic Surgery</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.hus.fi</url>
    <description>Website of the Helsinki University Hospital</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 19, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Janne J. Jokinen</investigator_full_name>
    <investigator_title>Consultant Cardiothoracic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>Simvastatin treatment</keyword>
  <keyword>Ischemia-reperfusion injury</keyword>
  <keyword>Lung failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
